Cyclerion Therapeutics, Inc. (CYCN)
CYCN Stock Price Chart
Explore Cyclerion Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CYCN price movements and trends.
CYCN Company Profile
Discover essential business fundamentals and corporate details for Cyclerion Therapeutics, Inc. (CYCN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Mar 2019
Employees
1.00
Website
https://www.cyclerion.comCEO
Regina M. Graul
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
CYCN Financial Timeline
Browse a chronological timeline of Cyclerion Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 12 Nov 2025
Earnings released on 5 Aug 2025
EPS came in at -$0.11 , while revenue for the quarter reached $93.00K .
Earnings released on 6 May 2025
EPS came in at -$0.56 , while revenue for the quarter reached $81.00K .
Earnings released on 4 Mar 2025
EPS came in at $0.22 , while revenue for the quarter reached $1.81M .
Earnings released on 14 Nov 2024
EPS came in at -$0.29 , while revenue for the quarter reached $194.00K .
Earnings released on 7 Aug 2024
EPS came in at -$0.53 .
Earnings released on 7 May 2024
EPS came in at -$0.62 .
Earnings released on 5 Mar 2024
EPS came in at -$0.68 surpassing the estimated -$7.40 by +90.75%.
Earnings released on 13 Nov 2023
EPS came in at -$0.93 surpassing the estimated -$6.40 by +85.47%.
Earnings released on 28 Jul 2023
EPS came in at -$1.83 surpassing the estimated -$5.60 by +67.32%.
Stock split effective on 16 May 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 May 2023
EPS came in at -$3.20 surpassing the estimated -$6.00 by +46.67%.
Earnings released on 22 Mar 2023
EPS came in at -$3.20 surpassing the estimated -$5.80 by +44.83%, while revenue for the quarter reached $1.63M , beating expectations by +167.27%.
Earnings released on 3 Nov 2022
EPS came in at -$4.80 surpassing the estimated -$7.00 by +31.43%.
Earnings released on 9 Aug 2022
EPS came in at -$6.20 surpassing the estimated -$6.80 by +8.82%, while revenue for the quarter reached $72.00K , missing expectations by -79.75%.
Earnings released on 4 May 2022
EPS came in at -$6.00 surpassing the estimated -$7.20 by +16.67%, while revenue for the quarter reached $225.00K , missing expectations by -59.09%.
Earnings released on 24 Feb 2022
EPS came in at -$4.80 surpassing the estimated -$6.40 by +25.00%, while revenue for the quarter reached $182.00K , missing expectations by -79.78%.
Earnings released on 9 Nov 2021
EPS came in at -$5.20 surpassing the estimated -$5.80 by +10.34%, while revenue for the quarter reached $77.00K , missing expectations by -79.95%.
Earnings released on 29 Jul 2021
EPS came in at -$9.00 , while revenue for the quarter reached $3.00M .
Earnings released on 30 Apr 2021
EPS came in at -$7.86 , while revenue for the quarter reached $62.00K .
Earnings released on 25 Feb 2021
EPS came in at -$11.00 falling short of the estimated -$0.19 by -5.69K%, while revenue for the quarter reached $133.00K , beating expectations by +18.75%.
Earnings released on 5 Nov 2020
EPS came in at -$11.80 falling short of the estimated -$0.56 by -2.01K%, while revenue for the quarter reached $400.00K , beating expectations by +5.36%.
CYCN Stock Performance
Access detailed CYCN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.